Yoshiyuki Abe
- Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism 7
- Oncology top 2%
- Drug Transport and Resistance Mechanisms 10
- Immunology and Allergy top 5%
- Molecular Biology top 5%
- Angiogenesis and VEGF in Cancer 21
- Glycosylation and Glycoproteins Research 7
- Immunology top 10%
-
- Vasculitis and related conditions 11
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 7
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 9
-
- Systemic Lupus Erythematosus Research 8
Yoshiyuki Abe
128 papers receiving 2.9k citations
Peers
Comparison fields: 5 of 108
- Cancer Research 741
- Oncology 1.0k
- Immunology and Allergy 143
- Molecular Biology 1.4k
- Immunology 419
Countries citing papers authored by Yoshiyuki Abe
This map shows the geographic impact of Yoshiyuki Abe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshiyuki Abe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshiyuki Abe more than expected).
Fields of papers citing papers by Yoshiyuki Abe
This network shows the impact of papers produced by Yoshiyuki Abe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshiyuki Abe. The network helps show where Yoshiyuki Abe may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yoshiyuki Abe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 0 | |
| 5 | 2023 | 7 | |
| 6 | 2023 | 5 | |
| 7 | 2023 | 1 | |
| 8 | 2022 | 16 | |
| 9 | 2010 | 11 | |
| 10 | 2008 | 187 | |
| 11 | 2008 | 108 | |
| 12 | Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme. | 2001 | 12 |
| 13 | Thrombospondin 2 gene expression is correlated with decreased vascularity in non-small cell lung cancer. | 1998 | 46 |
| 14 | [Clinicopathological study of pulmonary hamartoma with special reference to 6 patients who also had another tumor]. | 1996 | 0 |
| 15 | 1996 | 26 | |
| 16 | 1993 | 1 | |
| 17 | 1992 | 1 | |
| 18 | 1992 | 3 | |
| 19 | 1990 | 1 | |
| 20 | 1987 | 0 |
About Yoshiyuki Abe
Yoshiyuki Abe is a scholar working on Rheumatology, Oncology and Cancer Research, having authored 137 papers that have together received 2.9k indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (21 papers), Vasculitis and related conditions (11 papers), Drug Transport and Resistance Mechanisms (10 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (9 papers), Systemic Lupus Erythematosus Research (8 papers), Glycosylation and Glycoproteins Research (7 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (7 papers) and Cancer, Hypoxia, and Metabolism (7 papers). The work is most often cited by research in Cancer Research (741 citations), Oncology (1.0k citations) and Immunology and Allergy (143 citations). Yoshiyuki Abe has collaborated with scholars based in Japan, Canada and Czechia. Frequent co-authors include Masato Nakamura, Yoshito Ueyama, Hiroshi Kijima, Norikazu Tamaoki, H. Yamazaki, Y Oshika, Hiroyuki Hatanaka, Hitoshi Yamazaki, Tetsuji Tokunaga and T Tokunaga. Their work appears in journals such as The Journal of Immunology, JNCI Journal of the National Cancer Institute and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.